ANI Pharmaceuticals, Inc. · NASDAQ:ANIP

ANI Pharmaceuticals — Investor Presentation (November 2026)

38 slides from ANI Pharmaceuticals's investor presentation, Nov 16, 2026

  1. Slide 1: Corporate Presentation November 2026

    © 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation November 2026

  2. Slide 2: Forward-looking statements

    © 2026 ANI Pharmaceuticals, Inc. 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that are not historical

  3. Slide 3: Presentation of financial information

    © 2026 ANI Pharmaceuticals, Inc. 3 Presentation of financial information Non-GAAP Financial Measures Adjusted non-GAAP EBITDA ANI’s management considers adjusted non-GAAP EBITDA to be an important financial indicator of ANI’s operating performance, providing investors and analysts with a useful meas

  4. Slide 4: Egetis Therapeutics offer

    © 2026 ANI Pharmaceuticals, Inc. 4 Egetis Therapeutics offer This presentation includes discussion of our public offer for the shares, the convertible loan 2023:1 (the “Convertible”) and the warrants 2023/2033:1 (the “Warrants”) of Egetis, a Swedish public limited liability company (the “Offer”), wh

  5. Slide 5: High-growth, profitable biopharma transforming into a leading Rare Disease company

    © 2026 ANI Pharmaceuticals, Inc. 5 Generics business • Generates strong cash flows to support Rare Disease business growth Rare Disease business • >50% of total revenues in 2026 • Lead asset, Cortrophin Gel, expected to provide substantial, durable multi-year growth opportunity • Offer to acquire Eg

  6. Slide 6: Proven track record of delivering top- and bottom-line growth

    © 2026 ANI Pharmaceuticals, Inc. 6 Proven track record of delivering top- and bottom-line growth​ Adjusted Non-GAAP EBITDA ($ millions)(1)Total Company Net Revenues ($ millions) 1. Adjusted Non-GAAP EBITDA is a Non-GAAP financial measure. See Appendix for a reconciliation to the most directly compar

  7. Slide 7: 2026 strategic priorities to drive long-term growth

    © 2026 ANI Pharmaceuticals, Inc. 7 2026 strategic priorities to drive long-term growth Accelerate transformation into leading Rare Disease company • Maximize Cortrophin multi- year growth opportunity in existing specialties and gout expansion • Return ILUVIEN to growth through established commercial

  8. Slide 8: Executing 2026 priorities: accelerating transformation to a rare disease company

    © 2026 ANI Pharmaceuticals, Inc. 8 Executing 2026 priorities to drive long-term growth and value creation Accelerating transformation to a leading rare disease company $138.7M 3Q26 net revenues +36% YoY ✓ Existing specialties: continued momentum in 3Q26 ✓ Gout expansion: strong demand generation and

  9. Slide 9: Executing 2026 priorities: Generics and capital allocation

    © 2026 ANI Pharmaceuticals, Inc. 9 Executing 2026 priorities to drive long-term growth and value creation Continued excellence in Generics business Disciplined capital allocation strategy Generated 3Q26 Generics revenue of $104.5M, up 11% YoY Launched 16 generic products year-to-date Maintained #2 C

  10. Slide 10: 2026 financial guidance

    © 2026 ANI Pharmaceuticals, Inc. 10 1. Adjusted Non-GAAP EBITDA and Adjusted Non-GAAP Diluted EPS are Non-GAAP financial measures. 2. For full year 2026 guidance, Adjusted Non-GAAP Diluted EPS is defined as adjusted Non-GAAP net income divided by the diluted weighted average shares outstanding durin

  11. Slide 11: Rare Disease Business

    © 2026 ANI Pharmaceuticals, Inc. 11 Rare Disease Business

  12. Slide 12: Rare Disease business primary driver of growth; >50% of 2026 revenues

    © 2026 ANI Pharmaceuticals, Inc. 12 Rare Disease business represents primary driver of growth; expected to account for >50% of revenues in 2026 1. Percent change calculated based on the midpoint of 2026 financial guidance range provided by the Company on November 5, 2026. 2. Alimera acquisition occu

  13. Slide 13: Purified Cortrophin Gel is an established medicine for autoimmune diseases

    © 2026 ANI Pharmaceuticals, Inc. 13 Purified Cortrophin Gel is an established medicine for the treatment of certain autoimmune diseases Purified Cortrophin Gel is a naturally derived drug product that contains adrenocorticotropic hormone (ACTH), which is extracted from porcine pituitary glands Trust

  14. Slide 14: Cortrophin steroid-dependent and steroid-independent activity

    © 2026 ANI Pharmaceuticals, Inc. 14 Cortrophin may possess both steroid-dependent and steroid-independent activity In the steroid-independent pathway, representing another potential mechanism, ACTH is thought to bind to all five MCRs ACTH is a hormone that binds to cell-surface proteins called melan

  15. Slide 15: ACTH market sales growth

    © 2026 ANI Pharmaceuticals, Inc. 15 2021 2022 2023 2024 2025 $594M $558M $537M $684M $1.0B ACTH MARKET SALES -6% -4% +27%YoY Growth +50% Acthar Gel Purified Cortrophin® Gel $1.3B +28% 2026e(1) Overall ACTH market growth driven by continued expansion into key indications • Expect continued strong mul

  16. Slide 16: Addressable patient populations across indications under-penetrated

    © 2026 ANI Pharmaceuticals, Inc. 16 Diagnosed ~9,900,0001 ~500,000 addressable annual flares ~285,000 addressable patients Acute Gout Flares Cortrophin Gel has strong multi-year growth potential with addressable patient populations across indications significantly under-penetrated ~36% receive treat

  17. Slide 17: Entering podiatry and primary care settings for gout

    © 2026 ANI Pharmaceuticals, Inc. 17 Unlocking a transformative growth opportunity for Cortrophin by entering podiatry and primary care settings Gout expansion represents a meaningful multi- year business expansion opportunity in a new physician audience of podiatrists and primary care physicians Pot

  18. Slide 18: New physician segment in acute gouty arthritis flares

    © 2026 ANI Pharmaceuticals, Inc. 18 New physician segment represents a sizeable growth opportunity in acute gouty arthritis flares PRIMARY CARE INTERNAL MEDICINE PODIATRY SPECIALIST Diagnosed ~9,900,0001 ACUTE GOUT FLARES ~36% receive treatment annually2 1.5 – 2 average flares per year3 ~8% receive

  19. Slide 19: Cortrophin Gel 3Q26 performance

    © 2026 ANI Pharmaceuticals, Inc. 19 Cortrophin Gel 3Q26 performance Strong demand generation in gout expansion 40% of prescribers initiated 2+ cases +67% growth in new prescriber base vs. 2Q26 2x new patient cases vs. 2Q26 • Balanced demand from podiatrists and primary care physicians • Expanding sp

  20. Slide 20: ILUVIEN long-acting ocular therapy for DME and NIU-PS

    © 2026 ANI Pharmaceuticals, Inc. 20 ILUVIEN is a long-acting ocular therapy approved for DME and chronic NIU-PS Designed to deliver 36-months of continuous CONTINUOUS MICRODOSING of fluocinolone acetonide (FAc) Diabetic Macular Edema (DME): • Chronic disease that is the leading cause of vision loss

  21. Slide 21: Returning ILUVIEN to growth across global markets

    © 2026 ANI Pharmaceuticals, Inc. 21 Returning ILUVIEN to growth across global markets New data support growth in NIU-PS indication with a focus on retina specialists Safety consistent with the known profile of corticosteroid implants; IOP and cataract monitoring remain key considerations for ongoing

  22. Slide 22: Offer to Acquire Egetis Therapeutics

    © 2026 ANI Pharmaceuticals, Inc. 22 Offer to Acquire Egetis Therapeutics

  23. Slide 23: Offer to acquire Egetis advances transformation into a Rare Disease company

    © 2026 ANI Pharmaceuticals, Inc. 23 Offer to acquire Egetis Therapeutics advances ANI’s transformation into a leading Rare Disease company EMCITATE addresses a devastating rare disease with severe lifelong morbidity, and substantial caregiver burden, aligning with ANI’s goal to bring innovative ther

  24. Slide 24: EMCITATE strong fundamentals with significant growth potential

    © 2026 ANI Pharmaceuticals, Inc. 24 EMCITATE has strong fundamentals with significant growth potential First and only FDA-approved treatment for peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare, X-linked disorder characterized by severe CNS hypothyroidism and simultaneous periphera

  25. Slide 25: Combined Egetis and ANI capabilities to drive successful launch

    © 2026 ANI Pharmaceuticals, Inc. 25 Combined Egetis and ANI capabilities to drive successful launch Experienced commercial and medical affairs team hired and onboarded Patient support program in partnership with PANTHERx® Rare in place Strong relationships with patients, caregivers and advocacy grou

  26. Slide 26: Transaction financial terms

    © 2026 ANI Pharmaceuticals, Inc. 26 Transaction financial terms Consideration • Cash tender offer of SEK 11.25 per share • Total offer value of SEK 5.6B (~$560M); net enterprise value of ~$434M reflects estimated net proceeds of Egetis’ PRV monetization(1) Financing • Funded by combination of existi

  27. Slide 27: Generics Business

    © 2026 ANI Pharmaceuticals, Inc. 27 Generics Business

  28. Slide 28: Robust, diversified pipeline and new product launch execution

    © 2026 ANI Pharmaceuticals, Inc. 28 $210 $269 $301 $384 2022 2023 2024 2025 Robust, diversified pipeline and new product launch execution • Robust pipeline in place with goal to deliver at least 15 new product launches annually; 16 products launched through Nov 5, 2026; ANI holds #2 CGT filing posit

  29. Slide 29: Brand Royalties

    © 2026 ANI Pharmaceuticals, Inc. 29 Brand Royalties

  30. Slide 30: Establishing collaborations to drive future value

    © 2026 ANI Pharmaceuticals, Inc. 30 Establishing collaborations to drive future value for our stakeholders Out-licensed intellectual property to Harmony Biosciences in January 2026 Harmony to utilize IP to expand its intellectual property estate for pitolisant and to develop a novel formulation Low

  31. Slide 31: U.S. Manufacturing Footprint

    © 2026 ANI Pharmaceuticals, Inc. 31 U.S. Manufacturing Footprint

  32. Slide 32: Revenue by country of origin for API and finished goods

    © 2026 ANI Pharmaceuticals, Inc. 32 United States 95% Europe 2% India 2% Others 1% United States 56% Europe 18% India 20% China 4% Others 2% 95% of ANI’s revenues come from finished goods manufactured in the U.S.; ~95% of revenues from products sold in the U.S. API by Country of Origin Finished Good

  33. Slide 33: U.S.-based manufacturing footprint with strong GMP track record

    © 2026 ANI Pharmaceuticals, Inc. 33 U.S.-based manufacturing footprint with strong GMP track record Baudette, MN 130k sf Baudette, MN Containment Facility - 47k sf East Windsor, NJ 120k sf Facility Overview and Capabilities • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space

  34. Slide 34: Summary

    © 2026 ANI Pharmaceuticals, Inc. 34 Summary

  35. Slide 35: ANI well positioned to deliver long-term growth and value creation

    © 2026 ANI Pharmaceuticals, Inc. 35 ANI well positioned to deliver long-term growth and value creation • Rare Disease expected to be >50% of total revenue in 2026 • Lead asset, Cortrophin Gel, expected to deliver +38-44% YoY growth in 2026 with substantial, multi-year growth opportunity(1) • Expandi

  36. Slide 36: Appendix

    © 2026 ANI Pharmaceuticals, Inc. 36 Appendix

  37. Slide 37: Adjusted Non-GAAP EBITDA calculation and GAAP reconciliation

    © 2026 ANI Pharmaceuticals, Inc. 37 Adjusted Non-GAAP EBITDA calculation and US GAAP to Non-GAAP reconciliation

  38. Slide 38: References for Cortrophin Gel Addressable Patient Population

    © 2026 ANI Pharmaceuticals, Inc. 38 References for Cortrophin Gel Addressable Patient Population Gout 1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford). 2019 Dec 1;58(12):2177-2180. doi: 10.1093/rheumatology/kez196. PMID: 31168609 2. Th

ANI Pharmaceuticals — Investor Presentation (November 2026) on 6ix